Literature DB >> 19958226

Tamoxifen-2-hydroxylpropyl-beta-cyclodextrin-aggregated nanoassembly for nonbreast estrogen-receptor-positive cancer therapy.

Jaya Shukla1, Uma Sharma, Rajarshi Kar, Indira Kumari Varma, Sanjay Juyal, Naranamangalam R Jagannathan, Guru P Bandopadhyaya.   

Abstract

BACKGROUND: Tamoxifen (Tam) is used for the treatment and prevention of estrogen-receptor-positive human breast and other cancers. Its use in ovarian cancer has not been well studied.
METHOD: We formulated and characterized a water-soluble Tam-2-hydroxylpropyl-beta-cyclodextrin (HPbetaCD; 1:2 M) complex.
RESULTS: The differential scanning calorimetery of Tam-HPbetaCD indicated the transition of Tam from crystalline to amorphous form on addition of HPbetaCD. (1)H-nuclear magnetic resonance nuclear overhauser effect cross-peaks between phenyl moieties of Tam and HPbetaCD, and downfield shifts in H-3 (0.26) and H-5 (0.29) protons of HPbetaCD suggested the inclusion of Tam in HPbetaCD cavity. Transmission-electron microscopy studies of HPbetaCD and the Tam-HPbetaCD complex revealed the formation of aggregated nanoassembly at 60-180 nm. Dimethyl thiazol diphenyltetrazolium bromide assay demonstrated 7.37 +/- 2.32% cell survival of OAW-42 cells with 3 microg/ml Tam concentration.
CONCLUSION: The Tam-HPbetaCD nanoassembly entered the cell owing to enhanced permeability and retention property of tumor cell and antiestrogenic Tam and, therefore, resulted in excellent anticancer efficacy in the ovarian cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958226     DOI: 10.2217/nnm.09.69

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  1 in total

1.  Nanotamoxifen Delivery System: Toxicity Assessment After Oral Administration and Biodistribution Study After Intravenous Delivery of Radiolabeled Nanotamoxifen.

Authors:  Jaya Shukla; Amit Kumar Dinda; Abhay Krishna Srivastava; Kamna Srivastava; Bhagwant Rai Mittal; Guru Pad Bandopadhyaya
Journal:  World J Nucl Med       Date:  2016 Jan-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.